Drugs of Abuse: Definitive Testing
Customize your policy alerts
Sign up for Centene Policy CP.MP.50 alerts
Get alerted when Policy CP.MP.50 changes without checking for updates manually.
Monitor payer policy activity
Outpatient definitive/confirmatory (quantitative) drug testing for drugs of abuse in urine and other specimens, governing medical necessity criteria, coding implications, and exclusions for Centene-affiliated health plans.
Modified criteria to require a presumptive test before a definitive test unless no reliable test is in existence.
HCPCS codes G0482 and G0483 were stated as not supporting coverage criteria; G0480 and G0481 support coverage criteria.
Authorization protocols added: testing for children 6 years of age is exempt from authorization and PA requests accepted up to 10 business days after specimen collection.
Presumptive drug testing criteria removed from this policy and moved to a separate policy (CP.MP.208).
Coverage Criteria
Covered: Confirmatory/Definitive Testing
Covered when ALL of the following are met (criteria grouped A, B, or C):
See children exemption and authorization timing separately
Derived from policy A sequence
Derived from policy B sequence
Covers therapeutic drug monitoring requests
Definitive Testing: Coverage Criteria (overview)
Covered when testing meets definitive method requirements and when one of the medical necessity conditions is met; presumptive testing generally required prior to definitive testing unless no reliable presumptive test exists.
See HCPCS G0480/G0481 descriptions
Presumptive test required before definitive testing unless no reliable presumptive test exists
Not medically necessary: Excessive number of tests
Explicit policy statement
Not medically necessary: Administrative and other exclusions
List is illustrative per policy
Operational exclusions
Testing performed for administrative purposes is considered not medically necessary. This includes screening required as a condition of employment or pre-employment, for continuation of employment, for school or community athletic participation, and for medico-legal or court-ordered screening unless the screening is specifically required by state regulation. Routine physicals, administrative exams (for example marriage, licensure, or insurance evaluations), and similar non-clinical uses are likewise excluded.
The following scenarios are explicitly listed as not medically necessary and may trigger claim denials: blanket orders or routine standing orders that apply a panel for all patients; reflex definitive testing when a presumptive point-of-care test has already been performed; physician standing orders that apply to all patients; billing separately for individual definitive test codes when those analytes are already included in an ordered panel; performing or ordering presumptive immunoassay testing from a reference laboratory without an appropriate physician order; and using immunoassay (IA) results from CLIA-waived devices (cups, dipsticks, cards, cassettes) as a basis for definitive testing when the presumptive test was not ordered per policy.
Outpatient confirmatory/definitive quantitative drug testing that includes greater than or equal to 14 drugs/drug classes is considered not medically necessary. Requests that exceed this threshold do not meet the policy's medical necessity criteria.
Screening asymptomatic patients is generally not medically necessary unless a specific covered indication is detailed elsewhere in the policy. Other listed situations that are NMN include use of testing for routine administrative exams, same-day multi-source screening across specimen types, and procedural or laboratory workflow scenarios described under the policy exclusions.
Covered Indications
Confirmatory/definitive testing when presumptive testing performed and results inconsistent with clinical picture, when provider expects a presumptive positive and quantitative levels inform management, or when serum therapeutic drug level is needed for medical treatment.
Confirmatory/definitive testing is covered when presumptive testing has been performed and results warrant definitive analysis, when provider expects presumptive positive and quantitative levels will inform management, or when a serum therapeutic drug level is needed for medical treatment.
Aligns with criteria set A
Aligns with criteria set B
Aligns with criteria set C
Definitive testing for individuals when clinically indicated and when presumptive testing has been performed and supports the need for definitive testing, or when no reliable presumptive test exists for the target drug(s).
Includes HCPCS descriptions
Coding
| 0011U | Prescription drug monitoring, evaluation by LC-MS/MS, oral fluid, reported as a comparison to an estimated steady-state range, per date of service |
| 80184 | Phenobarbital |
| 80320 | Alcohols |
| 80321 | Alcohol biomarkers; 1 or 2 |
| 80322 | Alcohol biomarkers; 3 or more |
| 80323 | Alkaloids not otherwise specified |
| 80326 | Amphetamines; 5 or more |
| 80335 | Antidepressants, tricyclic and other cyclicals; 1 or 2 |
| 80346 | Benzodiazepines; 1 to 12 |
| 80354 | Fentanyl |
| 0054U | Prescription monitoring; 14 or more classes/substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report |
| 0082U | Definitive test(s), 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive any number of drug classes |
| 0328U | Assay, definitive, 120 or more drugs and metabolites, urine, quantitative LC-MS/MS |
| G0480 | Definitive drug test(s), methods able to identify individual drugs and distinguish structural isomers, qualitative or quantitative, includes specimen validity testing, per 1 to 7 classes |
| G0481 | Definitive drug test(s), methods able to identify individual drugs and distinguish structural isomers, qualitative or quantitative, includes specimen validity testing, per 8 to 14 drug classes |
| G0480 | Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish between structural isomers; includes specimen validity testing; per 1 to 7 classes |
| G0481 | Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish between structural isomers; includes specimen validity testing; per 8 to 14 classes |
| 80367 | Added to coding tables supporting coverage criteria |
| 80368 | Added to coding tables supporting coverage criteria |
| 80369 | Added to coding tables supporting coverage criteria |
| 80370 | Added to coding tables supporting coverage criteria; description updated in background |
| 80372 | Added to coding tables supporting coverage criteria |
| 80373 | Added to coding tables supporting coverage criteria |
| 82077 | 2021 CPT-82077 added to list of codes that support coverage criteria |
| 0328U | Added to list of CPT codes that do not support coverage criteria |
| 0082U | Added to CPT codes that do not support coverage criteria |
| 0143U | Listed as not medically necessary (later removed when code deleted) |
| 0144U | Listed as not medically necessary (later removed when code deleted) |
| 0145U | Listed as not medically necessary (later removed when code deleted) |
| 0146U | Listed as not medically necessary (later removed when code deleted) |
| 0147U | Listed as not medically necessary (later removed when code deleted) |
| 0148U | Listed as not medically necessary (later removed when code deleted) |
| 0149U | Listed as not medically necessary (later removed when code deleted) |
| 0150U | Listed as not medically necessary (later removed when code deleted) |
Provider Actions & Requirements
Authorization timing and pediatric exemption
Requests for authorization will be accepted up to 10 business days after specimen collection and will be reviewed for medical necessity based on the criteria in this policy. Testing for children 6 years of age and younger is exempt from prior authorization.
- Authorization requests accepted up to 10 business days after specimen collection
- Children age 6 and under: exempt from authorization
Administrative-purpose testing excluded
Urine or other drug testing is not medically necessary when performed for administrative purposes. Examples include but are not limited to employment or pre-employment screening, continuation-of-employment requirements, school or athletic program screening, court-ordered or other medico-legal screening (unless required by state law), insurance eligibility or licensure examinations, routine physicals, or other non-clinical administrative requirements. Blanket orders, routine standing orders for all patients in a practice, and screening asymptomatic patients for administrative reasons are not supported.
- Excluded uses: employment/pre-employment, school/athletic screening, medico-legal/court-ordered (unless mandated), insurance/licensure exams, routine physicals for administrative purposes
- Also excluded: blanket orders, routine standing orders for all patients, asymptomatic screening for administrative reasons
Medical record documentation required
The medical record must document a history or clinical suspicion of illicit drug use or prescription medication misuse, noncompliance, or a high probability of non-adherence to a prescribed regimen. Documentation should include relevant clinical history, discussion of recent medication use with the member/enrollee, indications for testing, and how the test results will affect ongoing clinical management.
- Documented history or suspicion of illicit or prescription misuse, noncompliance, or high probability of non-adherence
- Record must include clinical history, discussion of recent medication/use, reason for testing, and impact on care
Presumptive testing prerequisite
A presumptive (preliminary/qualitative) test should generally be performed before ordering definitive/confirmatory testing. Definitive testing may be ordered without a prior presumptive test only when no reliable presumptive test exists for the substance in question (for example, certain synthetic cannabinoids) or when clinical circumstances make presumptive testing impractical.
- Presumptive testing is a prerequisite for definitive testing unless no reliable presumptive test exists (e.g., some synthetic cannabinoids)
- Definitive testing without a prior presumptive test is allowed when clinical circumstances or lack of reliable presumptive assays justify it
Presumptive before definitive
Definitive testing should be limited to the specific drug(s) or drug classes indicated by the presumptive test or by clinical suspicion. Reflex definitive testing following point-of-care presumptive testing is not supported when the presumptive test itself was already performed at point of care unless the coverage criteria for confirmatory testing are met and documentation supports the need for definitive identification or quantification.
- Definitive tests must target the specific drug(s)/classes indicated by the presumptive test or clinical scenario
- Reflex definitive testing after point-of-care presumptive testing is a denial risk unless criteria for confirmatory testing are met and documented
Ordering Requirements
Physician order required for presumptive and reflex definitive testing
A physician order is required for presumptive testing to be performed and for reflexing to definitive testing; presumptive testing generally should precede definitive testing except when no reliable presumptive test exists.
- Obtain and document a physician order before performing presumptive or reflex definitive testing.
Presumptive test generally required before definitive; pediatric PA exemption
A presumptive test is generally required before ordering definitive testing unless no reliable presumptive test exists; pediatric testing (≤6 years) is exempt from prior authorization requirements per the policy.
- If no reliable presumptive test exists for the target substance (e.g., synthetic cannabinoids), definitive testing may be ordered without a presumptive test.
- Testing for children 6 years of age is exempt from PA.
Not Covered
Comprehensive definitive testing panels that cover very large numbers of drug classes are listed as not supporting coverage. Examples of CPT codes representing such broad panels include 0054U, 0082U, and 0328U, which are cited in the policy as not supporting the coverage criteria.
Definitive testing billed using HCPCS codes G0482 (per 15–21 classes) or G0483 (per 22 or more classes) does not support coverage criteria in this policy. The policy supports HCPCS G0480 and G0481 (1–7 and 8–14 classes, respectively) but explicitly excludes claims billed using G0482 or G0483 from meeting the coverage requirements.
Definitions
Background
Drugs of abuse testing is used to monitor adherence to prescribed controlled substances and to detect misuse. Common initial presumptive/ screening methods are immunoassays (rapid, cost-effective but prone to false positives/negatives), while definitive/confirmatory testing employs analytic techniques such as GC‑MS or LC‑MS/MS to specifically identify and/or quantify drugs or metabolites with high sensitivity and specificity. Confirmatory testing is indicated when presumptive results are inconsistent with the clinical picture or when quantitative levels are needed to guide treatment.
Frequency Limits
Revision History
Modified criteria to require a presumptive test before a definitive test unless no reliable test is in existence; added indication for testing when a presumptive test is assumed positive but quantitative levels are required.
Revised I.A.1 wording from 'unless no reliable test is available' to 'unless no reliable test is in existence' and updated coding tables; stated that HCPCS codes G0482 and G0483 do not support coverage.
Renamed policy to 'Drugs of Abuse: Definitive Testing' and removed presumptive testing criteria into a new separate policy (CP.MP.208); removed previous UM language about PA exemption for children <6 and 10-day post-test PA window.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.